Novo Nordisk AS Class B
NOVO B: XCSE (DNK)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
DKK 922.00 | Phcyz | Frxqxlsq |
Novo Nordisk's Cardiometabolic Franchise and Wide Moat Boosted by GLP-1 Demand
Business Strategy and Outlook
As a pioneer in diabetes care, Novo has been in the business for over 85 years and claims 32% of the $50 billion-plus diabetes treatment market and roughly half of the more than $15 billion insulin market. Diabetes' prevalence is expected to soar in coming decades as a result of an increasingly overweight and aging population, and we expect Novo to maintain its wide moat as it continues to dominate in diabetes and obesity therapy innovation.